Integrating oral PrEP delivery among African women in a large HIV endpoint-driven clinical trial.
Ivana BeeshamJulia D WelchRenee HeffronMelanie PleanerLara KidoguchiThesla Palanee-PhillipsKhatija AhmedDeborah BaronElizabeth A BukusiCheryl LouwTimothy D MastroJennifer SmitJoanne R BattingMookho MalahlehaVeronique C BaileyMags BeksinskaDeborah DonnellJared M Baetennull nullPublished in: Journal of the International AIDS Society (2020)
There is a need for improved HIV prevention services in clinical trials with HIV endpoints, especially trials among African women. PrEP as a component of a comprehensive HIV prevention package provided to women in a large clinical trial is practical and feasible. Provision of PrEP within clinical trials with HIV outcomes should be standard of prevention.
Keyphrases
- clinical trial
- men who have sex with men
- hiv testing
- hiv positive
- antiretroviral therapy
- polycystic ovary syndrome
- hiv infected
- human immunodeficiency virus
- phase ii
- hepatitis c virus
- hiv aids
- pregnancy outcomes
- open label
- double blind
- primary care
- healthcare
- cervical cancer screening
- phase iii
- palliative care
- mental health
- insulin resistance
- metabolic syndrome
- pregnant women
- weight loss